Compare Abbott Laboratories (ABT) vs EPR Properties (EPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs EPR Properties — how do they compare? Abbott Laboratories trades at $111.08 (market cap $187.95B), while EPR Properties trades at $60.79 (market cap $4.58B). The key difference: Abbott Laboratories is far larger — about 41× EPR Properties's market cap, and EPR Properties pays the higher dividend (6.22%). Which is the better fit depends on your goals.
| ABT | EPR | |
|---|---|---|
Market Cap | $187.95B | $4.58B |
Sector | Health | Real Estate |
52-Week High | $136.62 | $64.32 |
52-Week Low | $82.57 | $48.71 |
Enterprise Value | $214.96B | $8.09B |
Dividend Yield | 2.32% | 6.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
EPR Properties trades at $60.81, up 0.68% on the day, with a bearish technical signal but strong fundamentals including a 91.41% gross margin and recent Q2 2026 FFO beat. The company raised full-year guidance after deploying $440 million in investments at an 8.5% cap rate, signaling growth momentum. Dividend payments remain consistent at $0.31 monthly, supported by a conservative 65% AFFO payout ratio.
Outlook is mixed: analyst consensus is a Buy with a $65.30 target (7% upside), but technicals and some sentiment caution near-term. Key risks include theater exposure and rising interest rates. The stock offers a 6% yield with potential for dividend growth, balancing income and moderate appreciation prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →
